Oruka Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORKA research report →
Range $120 – $200
Price Chart
About the company
Oruka Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
- CEO
- Lawrence Otto Klein
- IPO
- 1997
- Employees
- 68
- HQ
- Menlo Park, CA, US
Get TickerSpark's AI analysis on ORKA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.66B
- P/E
- -31.04
- PEG
- -0.57
- P/S
- 0.00
- P/B
- 4.33
- EV/EBITDA
- -30.77
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -20.76%
- ROIC
- -13.88%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-83,000-207.4%
- Op Income
- $-122,051,000
- Net Income
- $-105,433,000-25.9%
- EPS
- $-2.31+53.7%
- OCF Growth
- -52.5%
- FCF Growth
- -52.4%
- 52W High
- $115.52
- 52W Low
- $24.31
- 50D MA
- $94.97
- 200D MA
- $64.94
- Beta
- -0.39
- RSI (14)
- 28
- Avg Volume
- 896.59K
No earnings-call transcripts are available for ORKA yet.
- Free Float
- 84.2%
- Shares Outstanding
- 60.31M
- Float Shares
- 50.80M
of shares held by institutions
266 13F filers
Buy/sell ratio 0.25. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 9.06M | ▲ 1.63M |
| Blackrock, Inc. | 4.99M | ▲ 1.46M |
| Vr Adviser, LLC | 4.15M | 0 |
| Fairmount Funds Management LLC | 3.71M | 0 |
| Capital World Investors | 3.40M | ▲ 3.40M |
| Rtw Investments, LP | 3.14M | ▲ 1.08M |
| State Street Corp | 2.67M | ▲ 1.06M |
| Vanguard Group Inc | 2.45M | ▲ 676.87K |
| Vanguard Capital Management LLC | 2.36M | ▲ 501.34K |
| Paradigm Biocapital Advisors LP | 2.14M | ▼ 175.79K |
| Deep Track Capital, LP | 1.93M | ▼ 108.20K |
| Bellevue Group AG | 1.66M | ▲ 1.15M |
Held by 305 ETFs
Biggest fund positions in ORKA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Klein Lawrence Otto | other | 25,000 |
| Oct 1, 26 | Klein Lawrence Otto | other | 25,000 |
| Oct 1, 26 | Klein Lawrence Otto | sell | 16,246 |
| Oct 1, 26 | Klein Lawrence Otto | sell | 8,554 |
| Oct 1, 26 | Klein Lawrence Otto | sell | 200 |
| Sep 21, 26 | Agarwal Arjun | sell | 533 |
| Sep 21, 26 | Quinlan Paul T | other | 10,000 |
| Sep 21, 26 | Quinlan Paul T | other | 10,000 |
| Sep 21, 26 | Quinlan Paul T | sell | 2,900 |
| Sep 21, 26 | Quinlan Paul T | sell | 3,832 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ORKA coverage
Recent articles, reports, and earnings notes.
No research on ORKA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ORKA report →ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
zacks.com · Sep 24
Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy
benzinga.com · Sep 23
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
globenewswire.com · Sep 23
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
globenewswire.com · Sep 9
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know
zacks.com · Aug 28
BlackRock Inc. Purchases Shares of 4,990,181 Oruka Therapeutics, Inc. $ORKA
defenseworld.net · Aug 25
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
globenewswire.com · Aug 24
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
zacks.com · Aug 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.